Irbesartan Omnicals Omnicals Pharma, Unip. (Irbesartan)

Irbesartan, an angiotensin II receptor blocker, is employed to manage conditions linked to the renin‑angiotensin system.

• Hypertension: lowers elevated blood pressure, reducing cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Proteinuria in diabetes: decreases urinary protein excretion, supporting renal protection.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth‑muscle and adrenal cells. By preventing angiotensin II binding, it inhibits vasoconstriction and aldosterone release, leading to vasodilation, reduced sodium and water retention, and lowered systemic vascular resistance, which together lower blood pressure and lessen renal stress. The blockade also diminishes sympathetic activation and mitigates pathological remodeling of the heart and kidneys.

Irbesartan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate cranial pain.
• Fatigue: general feeling of tiredness.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or throat requiring urgent care.
• Acute renal failure: sudden decline in kidney function, indicated by rising creatinine.
• Hyperkalemia: elevated blood potassium that can affect heart rhythm.
• Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.

When prescribing Irbesartan, clinicians should observe several safety considerations to minimize risk.

• Monitor blood pressure: adjust dosage if target levels are not achieved.
• Assess renal function: perform periodic serum creatinine and eGFR tests.
• Check serum potassium: watch for hyperkalemia, especially with concomitant potassium‑sparing agents.
• Avoid use in pregnancy: teratogenic risk (category D) may cause fetal harm.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.
• ACE inhibitors or other ARBs: additive hypotensive effect and renal risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect kidney function.
• Lithium: reduced clearance can raise lithium levels and toxicity risk.
• Cyclosporine or tacrolimus: may increase serum creatinine and potassium.